Elena Incerti

Elena Incerti

Auto-generated profile, based on publicly available information

Elena Incerti

Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2015 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TTT Touvier
T Touvier
Clara De PalmaClara De Palma
Clara De Palma
ERE Rigamonti
E Rigamonti
ASA Scagliola
A Scagliola
EIE Incerti
E Incerti
SBSilvia Brunelli
Silvia Brunelli
Mitochondrial fission and fusion are essential processes in the maintenance of the skeletal muscle function. The contribution of these processes to muscle development has not been properly investigated in vivo because of the early lethality of the models generated so far. To define the role of mitochondrial fission in muscle development and repair, we have generated a transgenic mouse line that overexpresses the fission-inducing protein Drp1 specifically in skeletal muscle. These mice displayed a drastic impairment in postnatal muscle growth, with reorganisation of the mitochondrial network and reduction of mtDNA quantity, without the deficiency of mitochondrial bioenergetics. Importantly we found that Drp1 overexpression activates the stress-induced PKR/eIF2α/Fgf21 pathway thus leading to an attenuated protein synthesis and downregulation of the growth hormone pathway. These results reveal for the first time how mitochondrial network dynamics influence muscle growth and shed light on aspects of muscle physiology relevant in human muscle pathologies.

8 February 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
EIElena Incerti
Elena Incerti
ETEnrico Tombetti
Enrico Tombetti
FFFederico Fallanca
Federico Fallanca
EBElena M. Baldissera
Elena M. Baldissera
Pierpaolo AlongiPierpaolo Alongi
Pierpaolo Alongi
Maria PicchioMaria Picchio
Maria Picchio
Purpose The object of this study was to assess whether 18F-fluorodeoxyglucose PET/CT (FDG PET/CT) provides novel information in patients with Takayasu’s arteritis (TA) in addition to that provided by current activity assessment, to analyse the effects of possible confounders, such as arterial grafts, and to verify whether PET/CT could be informative in lesions <4 mm thick. Methods We studied 30 patients with TA, evaluated from October 2010 to April 2014 by both PET/CT and magnetic resonance imaging (MRI). All arterial lesions were evaluated by PET both qualitatively (positive/negative) and semiquantitatively (maximum standardized uptake value, SUVmax), and the thickness of lesions in the MRI field of view was evaluated. In a per-patient analysis, the relationships between the PET data and acute-phase reactants and NIH criteria for active TA were evaluated. In a per-lesion analysis, the relationships between the PET features of each lesion and MRI morphological data were evaluated. The effects of the presence of arterial grafts were also evaluated. Results Increased FDG uptake was seen in 16 of 30 patients (53%) and in 46 of 177 vascular lesions (26%). Significant periprosthetic FDG uptake was seen in 6 of 7 patients (86%) with previous vascular surgery and in 10 of 11 of grafts (91%). Graft-associated uptake influenced the PET results in three patients (10%) and the SUVmax values in five patients (17%). Of 39 lesions with significant FDG uptake, 15 (38%) were <4 mm thick. Lesion thickness was correlated with lesion SUVmax in FDG-avid lesions only. FDG arterial uptake was not associated with systemic inflammation or NIH criteria. Conclusions PET/CT reveals unique and fundamental features of arterial involvement in TA. PET/CT may be useful in the assessment of local inflammatory and vascular remodelling events independent of systemic inflammation during follow-up, even in lesions in which the arterial wall is <4 mm. The presence of arterial grafts is a potential confounder. Prospective studies are required to correlate PET findings with relevant clinical outcomes.

17 January 2015 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Maria PicchioMaria Picchio
Maria Picchio
PMPaola Mapelli
Paola Mapelli
VPV. Panebianco
V. Panebianco
PCP. Castellucci
P. Castellucci
EIE. Incerti
E. Incerti
Stefano FantiStefano Fanti
Stefano Fanti

2 October 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
PMPaola Mapelli
Paola Mapelli
EIElena Incerti
Elena Incerti
Francesco CeciFrancesco Ceci
Francesco Ceci
PCPaolo Castellucci
Paolo Castellucci
Stefano FantiStefano Fanti
Stefano Fanti
Maria PicchioMaria Picchio
Maria Picchio
Recurrence of prostate cancer is suspected when an increase in the prostate-specific antigen level is detected after radical treatment; the recurrence could be local relapse, distant relapse, or both. Differentiation between the two patterns of relapse is critical for choosing the proper treatment strategy. Choline PET/CT could be of help in discriminating patients with local, lymph node, and bone recurrences, thus having an impact on patient management.

24 May 2016 in BJU International
Verified
Journal Article
Closed access
PDF file
AFAndrei Fodor
Andrei Fodor
GBGenoveffa Berardi
Genoveffa Berardi
Claudio FiorinoClaudio Fiorino
Claudio Fiorino
Maria PicchioMaria Picchio
Maria Picchio
EBElena Busnardo
Elena Busnardo
NMNadia G Di Muzio
Nadia G Di Muzio

16 February 2017 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
ASAnnarita Savi
Annarita Savi
EIElena Incerti
Elena Incerti
FFFederico Fallanca
Federico Fallanca
VBValentino Bettinardi
Valentino Bettinardi
FRFrancesca Rossetti
Francesca Rossetti
Maria PicchioMaria Picchio
Maria Picchio
18F-labeled fluoroazomycinarabinoside (18F-FAZA) is a PET biomarker for noninvasive identification of regional tumor hypoxia. The aim of the present phase I study was to evaluate the biodistribution and dosimetry of 18F-FAZA in non–small cell lung cancer patients. Methods: Five patients awaiting surgical resection of histologically proven or radiologically suspected non–small cell lung cancer were prospectively enrolled in the study. The patients underwent PET/CT after injection of 371 ± 32 MBq of 18F-FAZA. The protocol consisted of a 10-min dynamic acquisition of the heart to calculate the activity in blood, followed by 4 whole-body PET/CT scans, from the vertex to the mid thigh, at 10, 60, 120, and 240 min after injection. Urine samples were collected after each imaging session and at 360 min after injection. Volumes of interest were drawn around visually identifiable source organs to generate time–activity curves. Residence times were determined from time–activity curves, and effective doses to individual organs and the whole body were calculated using OLINDA/EXM 1.2 for the standard male and female phantoms. Results: Blood clearance was characterized by a rapid distribution followed by first-order elimination. The highest uptake was in muscle and liver, with respective percentage injected activity (%IA) peaks of 42.7 ± 5.3 %IA and 5.5 ± 0.6 %IA. The total urinary excretion was 15 %IA. The critical organ, with the highest absorbed radiation doses, was the urinary bladder wall, at 0.047 ± 0.008 and 0.067 ± 0.007 mGy/MBq for the 2- and 4-h voiding intervals, respectively. The effective doses for the standard male and female phantoms were 0.013 ± 0.004 and 0.014 ± 0.004 mSv/MBq, respectively, depending on the voiding schedule. Conclusion: With respect to the available literature, the biodistribution of 18F-FAZA in humans appeared to be slightly different from that in mice, with a low clearance in humans. Therefore, use of animal data may moderately underestimate radiation doses to organs in humans. Our dosimetry data showed that a 370-MBq injection of 18F-FAZA is safe for clinical use, similar to other widely used PET ligands. In particular, the effective dose is not appreciably different from those obtained with other hypoxia tracers, such as 18F-fluoromisonidazole.